Adaptive trial design: Its growing role in clinical research and implications for pharmacists

Cirulli, Joshua; McMillian, Wesley D.; Saba, Mojdeh; Stenehjem, David
May 2011
American Journal of Health-System Pharmacy;5/1/2011, Vol. 68 Issue 9, p807
Academic Journal
Purpose. Current trends and recent developments in use of adaptive trial design methodology for pharmaceutical research, as well as barriers to wider acceptance and implications for pharmacists, are discussed. Summary. Traditional clinical drug trials typically take many months or years to complete. In contrast, trials incorporating adaptive design elements allow researchers to make midstudy adjustments so that trial objectives are addressed more efficiently. Properly designed adaptive trials can enable researchers to conclude trials of unsuccessful treatments earlier or bring effective drugs to market sooner, improving patient safety and yielding substantial time and cost savings. Challenges and concerns with adaptive trial methodology include inadequate knowledge of adaptive design techniques among health care professionals and increased potential for bias or misinterpretation of trial results stemming from earlier access to data. Over the past decade, U.S. and European regulatory bodies have issued a number of documents to better define acceptable practices for designing, conducting, and reporting the results of adaptive trials, including updated Food and Drug Administration guidance released in 2010. Pharmacists need to stay current with developments in the field to properly assess and interpret trial results. Conclusion. Adaptive trial design is an emerging study methodology that allows for design modifications during a study, with the objective of implementing trial data as early as possible for the benefit of patients and the drug development process.


Related Articles

  • What does future hold for drug trial victims? Geddes, Linda // New Scientist;8/12/2006, Vol. 191 Issue 2564, p10 

    The article reports that the trial of the drug TGN1412 in Great Britain hit the volunteers who suffered adverse reactions. They are at risk of cancer and serious autoimmune disease. Richard Powell of Queen's Medical Centre in Nottingham, England, commissioned Richard Powell to estimate the...

  • Idebenone at 'Deadend' with Second Pivotal Trial Failure. Sheridan, Cormac // BioWorld International;5/26/2010, Vol. 15 Issue 21, p1 

    The article reports on the decision of Santhera Pharmaceutical Holdings AG to issue a dead-end for its Friedreich's ataxia (FRDA) program after reaching the second Phase III trial failure of idebenone. The trial showed a progressive neuromuscular degenerative condition associated with the drug....

  • TeGenero sinks.  // New Scientist;7/15/2006, Vol. 191 Issue 2560, p5 

    The article reports on the failure of clinical trials conducted by Würzburg, Germany-based TeGenero AG for its drug TGN1412, which was developed to dampen the immune system. Six healthy people almost died during the clinical trials due to adverse reactions caused by the drug. The purpose of...

  • Drug conclusion.  // New Scientist;4/15/2006, Vol. 189 Issue 2547, p7 

    The article reports that the "unprecedented" reaction that left six healthy volunteers fighting for their lives during a drug safety trial in London, England, last month was an unexpected biological effect of the drug itself. The drug, TGN1412, triggered widespread inflammation when it was...

  • Obesity, Lipids, and Diabetes. Henderson, Lisa // Applied Clinical Trials;Oct2009, Vol. 18 Issue 10, p22 

    The article reports on the successes and challenges that clinical trials face in addressing interrelated conditions such as obesity, lipids and diabetes. It mentions the development of obesity drugs in the U.S. which were withdrawn from the market after reports on heart disease, pulmonary...

  • All clear for now. Barry, Isobel // Nature Reviews Cancer;Oct2008, Vol. 8 Issue 10, p738 

    The article discusses the results of a clinical trial of Inegy, a combination of ezetimibe with the generic statin simvastatin configured to lower cholesterol. In July 2008, higher cancer incident was reported among the treated group. Researchers on Simvastin and Ezetimibe in Aortic Stenosis...

  • Warnings issued over COX 2 inhibitors in US and UK. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);1/1/2005, Vol. 330 Issue 7481, p9 

    Reports that warnings were issued in December 2004 regarding two COX 2 (cyclo-oxygenase-2) inhibitors because of fears that they might increase the risk of cardiovascular events, including heart attacks and strokes. How Celecoxib (Celebrex) showed an increase risk in a long term study, sponsored...

  • Xanthus: more hurdles to clear for Symadex.  // PharmaWatch: Cancer;Mar2006, Vol. 5 Issue 3, p11 

    The article reports that Xanthus Life Sciences Inc. has started a phase II clinical trial of Symadex drug candidate for the treatment of colorectal cancer. The drug candidate is designed to have similar or improved effectiveness compared to mitoxantrone and anthracyclines but with reduced...

  • PREVENTING COLORECTAL ADENOMAS.  // Bandolier;Nov2006, Vol. 13 Issue 11, p1 

    The article discusses the results of two trials comparing the efficacy of celecoxib with placebo in preventing adenoma formation. The protocols for both trials were similar, including the way the patients were screened for the study. Forty percent of the adenomas reported for both trials were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics